CANCER CLINICAL TRIALS NEWSLETTER
|
|
The purpose of this study is to determine anti-tumor activity by measuring overall response rate in recurrent and/or metastatic HNSCC patients receiving the combination of metformin and pembrolizumab. Patients will be randomized into arms 1 and 2, to either receive Metformin prior to pembrolizumab or to begin Metformin after pembrolizumab treatment begins. Metformin will be administered daily via an oral tablet either before or after pembrolizamab begins, and pembrolizamab will be administered via IV infusion every 3 weeks.
(UCCI-HN-19-01, IRB 2020-0365)
|
|
|
Questions? Please call us at 513-584-7698, or email us!
|
|
|
Our phone-based research recruitment app has features updates and a new look! It is available to all UC Cancer Center members and outside colleagues to aid in patient recruitment into cancer and other research studies.
Have you ever wanted to discuss research participation with a patient, but didn’t have the necessary study information at your fingertips to do so? The UC Cancer Center has partnered with High Enroll, LLC, to provide a valuable tool to solve this problem. This new phone-based application is available for all UC and non-UC referring providers. The new app allows for the entire recruiting portfolio of UC Cancer Center studies to always be updated by the research team. For each study, a summary, inclusion and exclusion criteria, other pertinent study information, and a “one-touch” contact button for the primary research coordinator are included
It takes only seconds to get the new app. On your phone, simply go to https://ctra.highenroll.org. Add the app to your home screen for quick and easy use. Please delete all other prior versions of the app.
If you have any questions, please research out to your UC Cancer Center research team or High Enroll members, Dr. Dylan Steen @ 908-208-6927, dlsteen@highenroll.org or Ginger Conway @859-992-5339, gaconway@highenroll.org.
|
Thanks,
Dylan and Ginger

|
|
|
UC study sheds light on cancer treatment, COVID-19
University of Cincinnati researchers have found that certain treatments for cancer may increase the chance of death if they contract COVID-19. Of the 3,600 patients analyzed from 122 institutions across the country, we found that 30-day mortality was highest among cancer patients treated one to three months prior to COVID-19 diagnosis and was highest for those treated with a chemotherapy/immunotherapy combination.
.
|
|
|
University of Cincinnati Cancer Center Symposium on Tumor Microenvironment 2020
Friday, Oct. 16, 2020 | 9:00 a.m.- 2:00 p.m
Virtual Event Access: TMSymposium.provirtualevent.com
For more information or questions, email kelly.hummel@uc.edu, or call 513-558-2030.
View Flyer as PDF
|
|
CANCER CLINICAL TRIALS NEWSLETTER
|
|
Questions? Please call us at 513-584-7698, or email us!
|
|
|
|
|